Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, UnitedHealth Group, Johnson & Johnson, and AbbVie. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$813.55 +11.90 (+1.48%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$811.00 -2.55 (-0.31%)
As of 03/14/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The stock has a strong buy rating from analysts, with eighteen analysts giving it a buy rating, indicating confidence in the company's future performance.
  • Eli Lilly and Co recently announced a stock buyback program worth $15 billion, which suggests that the management believes the stock is undervalued and is committed to enhancing shareholder value.
  • The current stock price is approximately $823.95, which is significantly below the average target price of $1,009.72 set by analysts, indicating potential for price appreciation.

Cons of Eli Lilly and Company

  • The company recently reported an EPS of $5.32, which missed analysts' consensus estimate of $5.45, raising concerns about its ability to meet growth expectations.
  • Eli Lilly and Co has a high P/E ratio of 70.36, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • The debt-to-equity ratio stands at 2.00, suggesting that the company is heavily leveraged, which could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$771.38 billion
P/E Ratio
69.47
Consensus Rating
Moderate Buy
Consensus Price Target
$1,009.72 (+24.1% Upside)
Volume
3.10 million shares
Average Volume
3.13 million shares
Today's Range
$800.00
$815.21
50-Day Range
$726.24
$930.22
52-Week Range
$711.40
$972.53
Dividend Yield
0.69%
UnitedHealth Group stock logo

2. UnitedHealth Group NYSE:UNH

$488.52 +7.00 (+1.45%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$486.08 -2.44 (-0.50%)
As of 03/14/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • UnitedHealth Group recently reported a strong quarterly earnings per share (EPS) of $6.81, exceeding analysts' expectations, which indicates robust financial performance and potential for future growth.
  • The company has a solid revenue growth of 6.8% year-over-year, reflecting its ability to expand its market presence and increase sales, which is a positive sign for investors.
  • UnitedHealth Group has declared a quarterly dividend of $2.10, translating to an annualized dividend of $8.40, providing a steady income stream for investors and demonstrating the company's commitment to returning value to shareholders.

Cons of UnitedHealth Group

  • Despite recent growth, UnitedHealth Group's revenue for the latest quarter was slightly below analysts' expectations, which may raise concerns about its ability to meet future targets.
  • The stock has experienced fluctuations, with a 12-month high of $630.73 and a low of $436.38, indicating potential volatility that could affect investor returns.
  • Analysts have varying price targets, with some as low as $595, which could create uncertainty regarding the stock's future performance and investor sentiment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$446.85 billion
P/E Ratio
31.52
Consensus Rating
Buy
Consensus Price Target
$629.32 (+28.8% Upside)
Volume
3.91 million shares
Average Volume
4.90 million shares
Today's Range
$478.24
$489.45
50-Day Range
$461.09
$548.65
52-Week Range
$436.38
$630.73
Dividend Yield
1.70%
Johnson & Johnson stock logo

3. Johnson & Johnson NYSE:JNJ

$162.94 -0.05 (-0.03%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$162.51 -0.43 (-0.26%)
As of 03/14/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • Johnson & Johnson recently reported earnings per share (EPS) of $2.04, exceeding analysts' expectations of $1.99, indicating strong financial performance and effective management.
  • The company has a solid market capitalization of $392.71 billion, reflecting its stability and potential for growth in the healthcare sector.
  • With a current stock price of $163.11, Johnson & Johnson is positioned well within its 1-year trading range, suggesting it may be a good entry point for investors.

Cons of Johnson & Johnson

  • Despite recent growth, Johnson & Johnson's stock has experienced a decline of 1.7%, which may indicate potential volatility and investor uncertainty.
  • The company has a price-to-earnings (P/E) ratio of 24.53, which is relatively high, suggesting that the stock may be overvalued compared to its earnings.
  • Johnson & Johnson's beta of 0.47 indicates lower volatility compared to the market, but this could also mean less potential for significant gains in a bullish market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$392.29 billion
P/E Ratio
24.50
Consensus Rating
Moderate Buy
Consensus Price Target
$171.33 (+5.2% Upside)
Volume
6.24 million shares
Average Volume
7.08 million shares
Today's Range
$161.10
$163.15
50-Day Range
$142.07
$167.57
52-Week Range
$140.68
$169.99
Dividend Yield
2.98%
AbbVie stock logo

4. AbbVie NYSE:ABBV

$211.90 +0.35 (+0.16%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$212.55 +0.66 (+0.31%)
As of 03/14/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • AbbVie has received multiple upgrades from brokerages, with Wells Fargo increasing their price target to $240.00, indicating strong confidence in the company's future performance.
  • The current stock price is $213.71, which is near its 52-week high of $218.66, suggesting strong market interest and potential for further growth.
  • AbbVie has a consensus rating of "Moderate Buy" from analysts, with a significant number of buy ratings, reflecting positive sentiment in the market.

Cons of AbbVie

  • Insiders have sold a total of 56,439 shares valued at over $11 million in the last 90 days, which may raise concerns about the company's future prospects.
  • The company's quick ratio of 0.55 and current ratio of 0.66 suggest potential liquidity issues, indicating that AbbVie may struggle to meet short-term obligations.
  • Despite recent upgrades, the stock's performance has been volatile, with a significant drop from its 52-week high, which could indicate underlying market concerns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$374.07 billion
P/E Ratio
88.29
Consensus Rating
Moderate Buy
Consensus Price Target
$211.45 (-0.2% Downside)
Volume
4.51 million shares
Average Volume
5.30 million shares
Today's Range
$208.29
$212.82
50-Day Range
$169.19
$216.62
52-Week Range
$153.58
$218.66
Dividend Yield
3.03%
Novo Nordisk A/S stock logo

5. Novo Nordisk A/S NYSE:NVO

$77.22 +1.33 (+1.76%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$77.12 -0.10 (-0.13%)
As of 03/14/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • Recent earnings report showed a strong performance with earnings per share of $0.91, exceeding analysts' expectations of $0.88, indicating robust financial health.
  • The stock is currently priced at $74.18, reflecting a significant drop from its 52-week high of $148.15, which may present a buying opportunity for investors looking for value.
  • Analysts have a consensus rating of "Moderate Buy" with an average price target of $145.25, suggesting potential upside for investors based on future performance expectations.

Cons of Novo Nordisk A/S

  • The stock has experienced a decline of approximately 5% recently, which may indicate volatility and uncertainty in the market.
  • Recent trading volumes have decreased significantly, with a 31% drop from the average daily volume, suggesting reduced investor interest or confidence.
  • Analysts have mixed ratings, with some firms downgrading their outlook, which could signal potential challenges ahead for the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$346.54 billion
P/E Ratio
23.47
Consensus Rating
Moderate Buy
Consensus Price Target
$145.25 (+88.1% Upside)
Volume
6.50 million shares
Average Volume
5.39 million shares
Today's Range
$75.24
$77.55
50-Day Range
$74.75
$90.94
52-Week Range
$73.80
$148.15
Dividend Yield
0.82%
Remove Ads
Merck & Co., Inc. stock logo

6. Merck & Co., Inc. NYSE:MRK

$94.72 +0.01 (+0.01%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$94.68 -0.05 (-0.05%)
As of 03/14/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • Merck's stock is currently trading at $93.76, which is relatively stable compared to its 52-week high of $134.63, indicating potential for recovery and growth.
  • Institutional investors hold a significant portion of Merck's stock, with 76.07% owned by such entities, suggesting strong confidence in the company's future performance.
  • Recent insider activity shows that a director purchased shares at an average cost of $88.25, indicating that those within the company believe the stock is undervalued.

Cons of Merck & Co., Inc.

  • Analysts have recently downgraded price targets, with Bank of America reducing its target from $118.00 to $112.00, which may indicate a lack of confidence in short-term growth.
  • Merck's stock has experienced a decline of 1.1% recently, which could signal potential volatility and uncertainty in the market.
  • Despite a strong institutional presence, the stock has a consensus rating of "Moderate Buy," suggesting that not all analysts are optimistic about its future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$239.27 billion
P/E Ratio
14.07
Consensus Rating
Moderate Buy
Consensus Price Target
$117.12 (+23.6% Upside)
Volume
12.68 million shares
Average Volume
10.13 million shares
Today's Range
$93.45
$94.88
50-Day Range
$83.01
$101.03
52-Week Range
$81.04
$134.63
Dividend Yield
3.42%
AstraZeneca stock logo

7. AstraZeneca NASDAQ:AZN

$77.60 +1.09 (+1.42%)
Closing price 03/14/2025 04:00 PM Eastern
Extended Trading
$77.44 -0.16 (-0.21%)
As of 03/14/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

  • AstraZeneca has received multiple upgrades from analysts, including a recent upgrade from UBS Group from a "neutral" to a "buy" rating, indicating strong confidence in the company's future performance.
  • The stock currently trades at $75.99, which is below its 12-month high of $87.68, suggesting potential for price appreciation as the market recognizes its value.
  • Institutional investors own 20.35% of AstraZeneca, reflecting a solid level of confidence from large financial entities, which can be a positive indicator for retail investors.

Cons of AstraZeneca

  • AstraZeneca's stock has experienced a recent decline of 1.9%, which may indicate short-term volatility and uncertainty in the market.
  • The company's price-to-earnings (P/E) ratio is currently at 33.62, which is relatively high and may suggest that the stock is overvalued compared to its earnings.
  • Recent institutional selling, such as Cookson Peirce & Co. reducing its stake by 99.3%, could signal a lack of confidence among some investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$237.27 billion
P/E Ratio
34.34
Consensus Rating
Buy
Consensus Price Target
$89.75 (+15.7% Upside)
Volume
5.97 million shares
Average Volume
5.76 million shares
Today's Range
$76.74
$77.69
50-Day Range
$65.37
$77.96
52-Week Range
$62.75
$87.68
Dividend Yield
2.73%
Novartis stock logo

8. Novartis NYSE:NVS

$109.15 +0.04 (+0.03%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$107.92 -1.23 (-1.13%)
As of 03/14/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • Novartis AG's stock is currently trading at $109.69, showing a recent increase of 1.0%, indicating positive market sentiment and potential for further growth.
  • The company has a strong market capitalization of $224.20 billion, which reflects its stability and ability to invest in research and development, crucial for long-term growth in the pharmaceutical sector.
  • Recent analyst ratings show a consensus rating of "Hold" with a target price of $123.38, suggesting that analysts believe the stock has room for appreciation.

Cons of Novartis

  • Several analysts have issued "underweight" ratings, indicating concerns about the stock's performance relative to the market, which could suggest limited upside potential.
  • Recent reports indicate that PNC Financial Services Group Inc. reduced its stake in Novartis AG by 3.8%, which may signal a lack of confidence among some institutional investors.
  • The stock has a relatively low beta of 0.53, indicating lower volatility compared to the market, which may limit potential high returns for aggressive investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$223.10 billion
P/E Ratio
18.56
Consensus Rating
Reduce
Consensus Price Target
$123.38 (+13.0% Upside)
Volume
1.27 million shares
Average Volume
1.41 million shares
Today's Range
$107.64
$109.30
50-Day Range
$97.51
$115.60
52-Week Range
$92.35
$120.92
Dividend Yield
2.18%
Abbott Laboratories stock logo

9. Abbott Laboratories NYSE:ABT

$127.02 -2.87 (-2.21%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$126.20 -0.82 (-0.65%)
As of 03/14/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • Abbott Laboratories has a strong dividend yield of 1.81%, providing investors with a steady income stream. The annualized dividend of $2.36 reflects the company's commitment to returning value to shareholders.
  • The stock is currently priced at approximately $128.50, which is considered attractive given the recent analyst upgrades and positive ratings, suggesting potential for price appreciation.
  • Recent analyst reports indicate a consensus rating of "Moderate Buy" with an average target price of $137.94, signaling confidence in the company's growth prospects and potential for stock price increases.

Cons of Abbott Laboratories

  • Recent insider sales, including a significant transaction where an executive vice president sold shares, may raise concerns about the company's short-term outlook and could indicate a lack of confidence among insiders.
  • The company's stock has seen a decrease in insider ownership, with insiders now holding only 0.47% of the company's stock, which may suggest a lack of alignment between management and shareholder interests.
  • Despite positive analyst ratings, the stock has experienced fluctuations, and the recent average price of $128.50 may not reflect its long-term potential, leading to uncertainty for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$220.29 billion
P/E Ratio
16.60
Consensus Rating
Moderate Buy
Consensus Price Target
$137.94 (+8.6% Upside)
Volume
9.54 million shares
Average Volume
5.60 million shares
Today's Range
$124.50
$128.49
50-Day Range
$110.96
$140.13
52-Week Range
$99.71
$141.23
Dividend Yield
1.72%
Thermo Fisher Scientific stock logo

10. Thermo Fisher Scientific NYSE:TMO

$523.44 +14.54 (+2.86%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$524.63 +1.18 (+0.23%)
As of 03/14/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The company recently reported earnings of $6.10 per share, exceeding analysts' expectations of $5.94, indicating strong financial performance and effective management.
  • Thermo Fisher Scientific Inc. has initiated a share buyback program authorizing the repurchase of $4.00 billion in outstanding shares, which can signal to investors that the management believes the stock is undervalued and can enhance shareholder value.
  • The company has increased its quarterly dividend to $0.43, reflecting a commitment to returning value to shareholders. This represents a 0.34% yield, which is an attractive feature for income-focused investors.

Cons of Thermo Fisher Scientific

  • Insider selling has been notable, with executives selling a total of 23,900 shares valued at over $13 million in the last three months, which may raise concerns about the company's future performance from a management perspective.
  • The recent decrease in insider ownership, with executives reducing their positions by 1.80% and 7.99%, could indicate a lack of confidence in the company's short-term prospects.
  • Despite strong earnings, the company's net margin of 14.78% may be lower than some competitors, suggesting potential challenges in maintaining profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$197.47 billion
P/E Ratio
31.67
Consensus Rating
Moderate Buy
Consensus Price Target
$653.23 (+24.8% Upside)
Volume
1.74 million shares
Average Volume
1.53 million shares
Today's Range
$508.71
$523.90
50-Day Range
$508.62
$607.06
52-Week Range
$493.30
$627.88
Dividend Yield
0.29%
Remove Ads
Intuitive Surgical stock logo

11. Intuitive Surgical NASDAQ:ISRG

$484.44 +7.66 (+1.61%)
Closing price 03/14/2025 04:00 PM Eastern
Extended Trading
$484.58 +0.13 (+0.03%)
As of 03/14/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • Recent upgrades from multiple analysts, including a target price increase from Morgan Stanley to $650.00, indicate strong market confidence in the company's growth potential.
  • The stock currently has a consensus rating of "Moderate Buy" with a target price averaging $613.10, suggesting that analysts expect the stock to perform well in the near future.
  • Intuitive Surgical, Inc. has a strong position in the minimally invasive surgery market, which is expected to grow, enhancing the company's revenue prospects.

Cons of Intuitive Surgical

  • Insider selling has been notable, with executives selling over 22,000 shares recently, which could signal a lack of confidence in the stock's short-term performance.
  • Despite positive analyst ratings, one analyst has issued a sell rating, indicating that there are differing opinions on the stock's future performance.
  • The healthcare sector can be volatile, and changes in regulations or market conditions could negatively impact Intuitive Surgical, Inc.'s business operations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$172.55 billion
P/E Ratio
75.58
Consensus Rating
Moderate Buy
Consensus Price Target
$613.10 (+26.6% Upside)
Volume
4.24 million shares
Average Volume
1.44 million shares
Today's Range
$476.57
$492.28
50-Day Range
$476.78
$610.45
52-Week Range
$364.17
$616.00
Dividend Yield
N/A
Amgen stock logo

12. Amgen NASDAQ:AMGN

$313.71 +1.07 (+0.34%)
Closing price 03/14/2025 04:00 PM Eastern
Extended Trading
$313.25 -0.46 (-0.15%)
As of 03/14/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • Amgen Inc. has a strong market capitalization of approximately $168 billion, indicating a robust position in the biotechnology sector, which can provide stability and growth potential for investors.
  • The company recently reported earnings per share (EPS) of $5.31, exceeding analysts' expectations of $5.04, showcasing its ability to generate profits and potentially leading to higher stock valuations.
  • Amgen Inc. has a current stock price of $313.11, reflecting a slight increase, which may indicate positive market sentiment and investor confidence in the company's future performance.

Cons of Amgen

  • The company has a high debt-to-equity ratio of 9.62, indicating that it relies heavily on debt financing, which can pose risks, especially in volatile market conditions.
  • Amgen Inc. has a dividend payout ratio of 126.09%, suggesting that it is paying out more in dividends than it is earning, which may not be sustainable in the long term.
  • Despite a strong performance, two analysts have rated the stock with a sell rating, indicating some skepticism about its future growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$168.53 billion
P/E Ratio
41.55
Consensus Rating
Hold
Consensus Price Target
$314.04 (+0.1% Upside)
Volume
2.40 million shares
Average Volume
2.56 million shares
Today's Range
$310.30
$314.51
50-Day Range
$258.59
$327.36
52-Week Range
$253.30
$346.85
Dividend Yield
2.91%
Danaher stock logo

13. Danaher NYSE:DHR

$211.09 +7.00 (+3.43%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$210.56 -0.53 (-0.25%)
As of 03/14/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • Danaher Co. has a strong market capitalization of approximately $146.69 billion, indicating a robust financial position and stability in the market.
  • The company recently reported earnings per share (EPS) of $2.14, meeting consensus estimates, which reflects consistent performance and reliability in earnings.
  • Danaher Co. has increased its quarterly dividend from $0.27 to $0.32 per share, demonstrating a commitment to returning value to shareholders. This translates to an annualized dividend yield of 0.62%, which can be attractive for income-focused investors.

Cons of Danaher

  • The price-to-earnings (P/E) ratio of 38.87 indicates that the stock may be overvalued compared to its earnings, which could pose a risk if earnings do not grow as expected.
  • Analysts have recently adjusted their price targets downward, with Citigroup lowering its target from $285.00 to $265.00, which may signal concerns about future performance.
  • The company has a price-to-earnings-growth (PEG) ratio of 2.66, suggesting that the stock's price may be high relative to its expected earnings growth, which could deter value investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$150.87 billion
P/E Ratio
39.98
Consensus Rating
Moderate Buy
Consensus Price Target
$277.76 (+31.6% Upside)
Volume
4.18 million shares
Average Volume
3.01 million shares
Today's Range
$205.11
$211.92
50-Day Range
$201.15
$250.51
52-Week Range
$196.80
$281.70
Dividend Yield
0.53%
Sanofi stock logo

14. Sanofi NASDAQ:SNY

$57.75 0.00 (0.00%)
Closing price 03/14/2025 04:00 PM Eastern
Extended Trading
$57.72 -0.03 (-0.06%)
As of 03/14/2025 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi's stock is currently priced at $59.25, reflecting a strong market position and potential for growth.
  • Recent upgrades from analysts, including a "strong-buy" rating from Sanford C. Bernstein, indicate positive sentiment and confidence in the company's future performance.
  • The company has seen significant institutional investment, with 14.04% of its stock owned by hedge funds and institutional investors, suggesting strong backing and confidence from major financial players.

Cons of Sanofi

  • Despite recent upgrades, some analysts have downgraded the stock from "buy" to "hold," indicating a cautious outlook that may suggest limited upside potential in the near term.
  • The stock has a relatively high P/E ratio of 23.80, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Sanofi's recent price performance shows fluctuations, with a 52-week low of $45.22, which may raise concerns about volatility and risk for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$146.56 billion
P/E Ratio
23.19
Consensus Rating
Buy
Consensus Price Target
$60.00 (+3.9% Upside)
Volume
1.76 million shares
Average Volume
2.24 million shares
Today's Range
$57.56
$57.93
50-Day Range
$48.45
$59.42
52-Week Range
$45.22
$60.12
Dividend Yield
2.49%
Pfizer stock logo

15. Pfizer NYSE:PFE

$25.74 +0.14 (+0.53%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$25.73 0.00 (-0.02%)
As of 03/14/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • Pfizer Inc. reported a strong earnings per share (EPS) of $0.63 for the latest quarter, exceeding analysts' expectations of $0.48, indicating robust financial performance.
  • The company achieved a revenue of $17.76 billion during the same quarter, surpassing the forecast of $17.26 billion, showcasing its ability to generate significant sales.
  • Pfizer Inc. has a market capitalization of $145.23 billion, reflecting its substantial size and stability in the biopharmaceutical sector, which can be attractive to investors seeking established companies.

Cons of Pfizer

  • Despite recent strong earnings, the company has a quick ratio of 0.73, which indicates potential liquidity issues, as it may struggle to meet short-term obligations without selling inventory.
  • Pfizer Inc. has received mixed ratings from analysts, with one sell rating and several neutral ratings, suggesting uncertainty about its future performance.
  • The debt-to-equity ratio of 0.63 indicates that the company has a moderate level of debt compared to its equity, which could pose risks if interest rates rise or if the company faces financial challenges.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$145.85 billion
P/E Ratio
18.25
Consensus Rating
Moderate Buy
Consensus Price Target
$31.92 (+24.0% Upside)
Volume
30.27 million shares
Average Volume
39.86 million shares
Today's Range
$25.50
$25.76
50-Day Range
$25.46
$27.12
52-Week Range
$24.48
$31.54
Dividend Yield
6.55%
Remove Ads
Boston Scientific stock logo

16. Boston Scientific NYSE:BSX

$97.26 +1.89 (+1.98%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$96.41 -0.85 (-0.87%)
As of 03/14/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The company recently reported earnings per share (EPS) of $0.70, exceeding analysts' expectations of $0.65, indicating strong financial performance and effective management.
  • Boston Scientific Co. has a solid market capitalization of $143.94 billion, which reflects its stability and growth potential in the medical device industry.
  • With a current stock price around $100.66, which is near its 50-day moving average, the stock may be seen as a stable investment opportunity for those looking to enter at a favorable price point.

Cons of Boston Scientific

  • The stock has a high price-to-earnings (PE) ratio of 77.91, which may suggest that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • Insider selling has been notable, with executives selling a total of 137,302 shares worth over $14 million in the last three months, which could indicate a lack of confidence in the company's short-term prospects.
  • The company has a relatively high price-to-earnings-growth (PEG) ratio of 2.79, which may imply that the stock is expensive relative to its expected growth rate, making it less attractive for value investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$143.53 billion
P/E Ratio
77.81
Consensus Rating
Buy
Consensus Price Target
$108.91 (+12.0% Upside)
Volume
4.92 million shares
Average Volume
5.76 million shares
Today's Range
$95.56
$97.39
50-Day Range
$91.21
$106.20
52-Week Range
$65.87
$107.17
Dividend Yield
N/A
Stryker stock logo

17. Stryker NYSE:SYK

$369.96 +6.30 (+1.73%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$369.52 -0.44 (-0.12%)
As of 03/14/2025 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The current stock price is $363.52, which may present a buying opportunity for investors looking for growth in the medical technology sector.
  • Stryker Co. has recently reported strong quarterly earnings, with an EPS of $4.01, surpassing analysts' expectations, indicating robust financial health and operational efficiency.
  • Analysts have a consensus rating of "Moderate Buy" for Stryker Co., with a price target of $421.90, suggesting potential upside for investors.

Cons of Stryker

  • The stock has experienced a decrease in insider ownership, with a notable 5.24% reduction, which may raise concerns about the confidence of current executives in the company's future.
  • Despite strong earnings, the high PE ratio of 46.85 suggests that the stock may be overvalued, which could deter value-focused investors.
  • Recent downgrades from analysts, including a shift from "buy" to "hold" by StockNews.com, indicate a potential slowdown in growth expectations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$141.17 billion
P/E Ratio
47.68
Consensus Rating
Moderate Buy
Consensus Price Target
$421.90 (+14.0% Upside)
Volume
1.80 million shares
Average Volume
1.22 million shares
Today's Range
$362.61
$371.76
50-Day Range
$355.17
$399.83
52-Week Range
$314.93
$406.19
Dividend Yield
0.91%
Gilead Sciences stock logo

18. Gilead Sciences NASDAQ:GILD

$111.44 -1.91 (-1.69%)
Closing price 03/14/2025 04:00 PM Eastern
Extended Trading
$111.34 -0.10 (-0.09%)
As of 03/14/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The stock is currently trading at approximately $100.56, which is near its 50-day simple moving average, indicating a stable price trend that may attract investors looking for consistency.
  • Gilead Sciences, Inc. recently increased its quarterly dividend from $0.77 to $0.79 per share, reflecting a commitment to returning value to shareholders. This increase represents an annualized dividend yield of 2.77%, which can be appealing for income-focused investors.
  • The company reported earnings per share (EPS) of $1.90 for the last quarter, surpassing analysts' expectations of $1.67. This positive earnings surprise can indicate strong operational performance and may boost investor confidence.

Cons of Gilead Sciences

  • The company has a high price-to-earnings (P/E) ratio of 308.08, which may indicate that the stock is overvalued relative to its earnings, potentially leading to a price correction.
  • Gilead Sciences, Inc. has a significant payout ratio of 854.05%, suggesting that it is paying out more in dividends than it is earning, which could be unsustainable in the long run.
  • The stock has a beta of 0.21, indicating lower volatility compared to the market. While this can be seen as a pro, it may also suggest limited growth potential, which could deter aggressive investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$138.78 billion
P/E Ratio
301.19
Consensus Rating
Moderate Buy
Consensus Price Target
$104.52 (-6.2% Downside)
Volume
8.65 million shares
Average Volume
8.23 million shares
Today's Range
$110.90
$113.36
50-Day Range
$89.14
$117.41
52-Week Range
$62.07
$119.96
Dividend Yield
2.69%
Vertex Pharmaceuticals stock logo

19. Vertex Pharmaceuticals NASDAQ:VRTX

$504.77 +1.85 (+0.37%)
Closing price 03/14/2025 04:00 PM Eastern
Extended Trading
$507.36 +2.60 (+0.51%)
As of 03/14/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • Vertex Pharmaceuticals Incorporated has received multiple "buy" ratings from analysts, indicating strong confidence in the company's future performance. This includes a recent upgrade from StockNews.com, which reflects positive sentiment in the market.
  • The stock is currently trading at $495.42, showing a recent increase of 1.4%. This upward movement suggests potential for further growth, making it an attractive option for investors looking for appreciation in stock value.
  • Vertex Pharmaceuticals Incorporated has a solid market capitalization of $127.22 billion, which indicates a strong position in the market and the ability to invest in research and development for new therapies.

Cons of Vertex Pharmaceuticals

  • The stock has a high price-to-earnings (P/E) ratio of -225.19, which indicates that the company is currently not profitable. This could be a red flag for investors looking for companies with stable earnings.
  • Insider selling has been observed, with executives selling a total of 4,315 shares worth over $2 million in the last quarter. This could signal a lack of confidence in the company's short-term prospects.
  • Despite the positive ratings, there are still ten analysts who have rated the stock as a "hold," suggesting that there may be uncertainty about its future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$129.62 billion
P/E Ratio
-229.44
Consensus Rating
Moderate Buy
Consensus Price Target
$506.70 (+0.4% Upside)
Volume
1.39 million shares
Average Volume
1.49 million shares
Today's Range
$502.26
$519.68
50-Day Range
$402.49
$504.77
52-Week Range
$377.85
$519.88
Dividend Yield
N/A
Bristol-Myers Squibb stock logo

20. Bristol-Myers Squibb NYSE:BMY

$59.01 -1.27 (-2.11%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$59.10 +0.09 (+0.16%)
As of 03/14/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol-Myers Squibb

Pros of Bristol-Myers Squibb

  • Bristol-Myers Squibb has a strong portfolio of biopharmaceutical products, including recent advancements in treatments for various cancers, such as Opdivo and Yervoy, which are leading therapies in their respective categories.
  • The company recently announced a quarterly dividend of $0.62, translating to an annualized dividend yield of 4.03%, which can provide a steady income stream for investors.
  • With a positive return on equity of 13.93%, Bristol-Myers Squibb demonstrates effective management in generating profits from shareholders' equity, indicating a potentially profitable investment.

Cons of Bristol-Myers Squibb

  • The company has a negative net margin of 18.53%, which indicates that it is currently spending more than it earns, raising concerns about its profitability and financial health.
  • Bristol-Myers Squibb's payout ratio is -56.11%, suggesting that the company is paying out more in dividends than it is earning, which may not be sustainable in the long term.
  • With only 0.09% of the stock owned by insiders, there may be a lack of alignment between management and shareholders, which can be a red flag for potential investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$119.75 billion
P/E Ratio
-13.35
Consensus Rating
Hold
Consensus Price Target
$57.86 (-2.0% Downside)
Volume
11.90 million shares
Average Volume
12.66 million shares
Today's Range
$58.72
$59.99
50-Day Range
$53.85
$63.00
52-Week Range
$39.35
$63.33
Dividend Yield
4.06%
Remove Ads
Medtronic stock logo

21. Medtronic NYSE:MDT

$93.18 +0.85 (+0.92%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$92.82 -0.36 (-0.39%)
As of 03/14/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • Medtronic plc reported earnings per share (EPS) of $1.39 for the latest quarter, exceeding analysts' expectations of $1.36. This indicates strong financial performance and can boost investor confidence.
  • The company has a solid market capitalization of $121.30 billion, reflecting its stability and potential for growth in the medical technology sector.
  • Medtronic plc has announced a quarterly dividend of $0.70 per share, translating to an annualized dividend of $2.80 and a yield of 2.96%. This consistent dividend payment can provide a reliable income stream for investors.

Cons of Medtronic

  • Despite beating EPS estimates, Medtronic plc's revenue of $8.29 billion fell short of the consensus estimate of $8.33 billion, which may raise concerns about future growth prospects.
  • The company has a relatively high dividend payout ratio of 85.11%, which could limit its ability to reinvest profits back into the business for expansion or innovation.
  • Analysts have mixed ratings on the stock, with one sell rating, eight hold ratings, and only six buy ratings, indicating uncertainty in the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$119.51 billion
P/E Ratio
28.32
Consensus Rating
Hold
Consensus Price Target
$96.07 (+3.1% Upside)
Volume
7.79 million shares
Average Volume
6.06 million shares
Today's Range
$92.12
$93.30
50-Day Range
$79.77
$94.58
52-Week Range
$75.96
$96.25
Dividend Yield
2.96%
Elevance Health stock logo

22. Elevance Health NYSE:ELV

$421.72 +4.47 (+1.07%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$415.97 -5.75 (-1.36%)
As of 03/14/2025 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$95.88 billion
P/E Ratio
16.47
Consensus Rating
Moderate Buy
Consensus Price Target
$517.03 (+22.6% Upside)
Volume
1.45 million shares
Average Volume
1.30 million shares
Today's Range
$414.53
$422.45
50-Day Range
$379.36
$423.44
52-Week Range
$362.21
$567.26
Dividend Yield
1.62%
The Cigna Group stock logo

23. The Cigna Group NYSE:CI

$313.35 +1.36 (+0.43%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$314.75 +1.41 (+0.45%)
As of 03/14/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about The Cigna Group

Pros of The Cigna Group

  • The Cigna Group recently declared a quarterly dividend of $1.51, which is an increase from the previous $1.40. This reflects a commitment to returning value to shareholders, with an annualized dividend yield of 1.88%.
  • The current stock price is approximately $308.12, which is near the company's 50-day moving average of $292.84, indicating potential stability and investor confidence in the stock.
  • The company has a solid return on equity of 18.61%, suggesting effective management and profitability, which can be attractive to investors looking for strong financial performance.

Cons of The Cigna Group

  • The company reported an EPS of $6.64 for the last quarter, which missed analysts' expectations of $7.84 by $1.20, indicating potential challenges in meeting growth targets.
  • The Cigna Group has a current ratio of 0.66, which is below 1, suggesting that the company may have difficulty meeting its short-term liabilities with its current assets.
  • With a debt-to-equity ratio of 0.70, The Cigna Group has a moderate level of debt compared to its equity, which could pose risks if interest rates rise or if the company faces financial difficulties.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$85.76 billion
P/E Ratio
25.60
Consensus Rating
Buy
Consensus Price Target
$372.31 (+18.8% Upside)
Volume
1.35 million shares
Average Volume
1.57 million shares
Today's Range
$309.55
$315.73
50-Day Range
$278.77
$326.87
52-Week Range
$262.03
$370.83
Dividend Yield
1.85%
CVS Health stock logo

24. CVS Health NYSE:CVS

$65.63 -0.12 (-0.18%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$65.60 -0.02 (-0.04%)
As of 03/14/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. recently reported earnings per share of $1.19, exceeding the consensus estimate of $0.89 by $0.30, indicating strong financial performance.
  • The stock is currently trading at $64.88, which is below the consensus target price of $69.83, suggesting potential for price appreciation.
  • Analysts have upgraded CVS Health Co. to a "buy" rating, with several firms increasing their price targets, reflecting positive sentiment in the market.

Cons of CVS Health

  • Insider activity shows a significant sale by a senior vice president, who reduced their position by 47.23%, which may indicate a lack of confidence in the stock's short-term performance.
  • The company's current ratio of 0.81 suggests potential liquidity issues, as it indicates that current liabilities exceed current assets.
  • CVS Health Co. has a debt-to-equity ratio of 0.80, which, while manageable, indicates that the company is using a significant amount of debt to finance its operations, potentially increasing financial risk.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$82.75 billion
P/E Ratio
17.93
Consensus Rating
Moderate Buy
Consensus Price Target
$69.82 (+6.4% Upside)
Volume
9.00 million shares
Average Volume
11.61 million shares
Today's Range
$65.46
$67.25
50-Day Range
$45.82
$66.35
52-Week Range
$43.56
$80.75
Dividend Yield
4.01%
GSK stock logo

25. GSK NYSE:GSK

$39.53 +0.31 (+0.78%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$39.55 +0.02 (+0.04%)
As of 03/14/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • GSK plc recently reported earnings per share (EPS) of $0.59, exceeding the consensus estimate of $0.44, indicating strong financial performance and potential for growth.
  • The stock is currently trading at $40.08, which reflects a positive trend and may attract investors looking for growth opportunities.
  • GSK plc has increased its quarterly dividend to $0.3932, up from $0.39, demonstrating a commitment to returning value to shareholders and indicating financial health.

Cons of GSK

  • Deutsche Bank recently downgraded GSK plc from a "buy" rating to a "hold" rating, indicating a more cautious outlook from analysts.
  • The stock has a relatively high price-to-earnings (P/E) ratio of 25.21, which may suggest that it is overvalued compared to its earnings potential.
  • GSK plc has a debt-to-equity ratio of 1.12, indicating that the company has a significant amount of debt compared to its equity, which could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$81.94 billion
P/E Ratio
24.86
Consensus Rating
Moderate Buy
Consensus Price Target
$43.25 (+9.4% Upside)
Volume
4.94 million shares
Average Volume
4.30 million shares
Today's Range
$39.05
$39.61
50-Day Range
$32.12
$40.41
52-Week Range
$31.72
$45.93
Dividend Yield
3.98%
Remove Ads
McKesson stock logo

26. McKesson NYSE:MCK

$650.96 +7.27 (+1.13%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$622.57 -28.39 (-4.36%)
As of 03/14/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • McKesson Co. has a strong market presence with a market capitalization of approximately $82.22 billion, indicating its stability and potential for growth in the healthcare sector.
  • The company recently reported earnings of $8.03 per share, which, despite missing estimates, reflects its ongoing profitability in a competitive market.
  • McKesson Co. has a current stock price of $656.09, which is near its 1-year high of $663.61, suggesting strong investor confidence and potential for further appreciation.

Cons of McKesson

  • McKesson Co. reported a net margin of only 0.82%, which may raise concerns about its profitability and efficiency compared to competitors.
  • The company has a negative return on equity of 181.26%, indicating that it is currently not generating profit from its equity investments, which could deter potential investors.
  • Recent insider selling, including a significant transaction by the CEO, may signal a lack of confidence in the company's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$80.67 billion
P/E Ratio
29.81
Consensus Rating
Moderate Buy
Consensus Price Target
$649.36 (-0.2% Downside)
Volume
767,224 shares
Average Volume
792,515 shares
Today's Range
$639.17
$651.89
50-Day Range
$580.34
$659.53
52-Week Range
$464.42
$663.62
Dividend Yield
0.44%
HCA Healthcare stock logo

27. HCA Healthcare NYSE:HCA

$319.82 +5.03 (+1.60%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$319.50 -0.32 (-0.10%)
As of 03/14/2025 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • HCA Healthcare, Inc. reported a strong earnings per share (EPS) of $6.22 for the latest quarter, exceeding analysts' expectations of $6.03. This indicates robust financial performance and potential for continued growth.
  • The company has a high return on equity (ROE) of 586.47%, suggesting that it is highly effective at generating profits from its equity investments, which can be attractive to investors looking for efficient management.
  • HCA Healthcare, Inc. recently increased its quarterly dividend to $0.72 per share, reflecting a commitment to returning value to shareholders. This increase from the previous dividend of $0.66 indicates confidence in future earnings.

Cons of HCA Healthcare

  • Recent analyst downgrades, including a reduction in price targets by firms like Barclays and Bank of America, may indicate a lack of confidence in the stock's short-term performance.
  • One analyst has issued a sell rating on HCA Healthcare, Inc., which could signal potential risks or concerns about the company's future performance.
  • Insider selling activity, such as the recent sale of 9,533 shares by a senior vice president, may raise concerns about the company's outlook from those who are closely involved with its operations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$78.74 billion
P/E Ratio
14.56
Consensus Rating
Moderate Buy
Consensus Price Target
$385.67 (+20.6% Upside)
Volume
1.04 million shares
Average Volume
1.71 million shares
Today's Range
$313.21
$321.50
50-Day Range
$296.45
$336.93
52-Week Range
$289.98
$417.14
Dividend Yield
0.79%
Regeneron Pharmaceuticals stock logo

28. Regeneron Pharmaceuticals NASDAQ:REGN

$666.87 -13.74 (-2.02%)
Closing price 03/14/2025 04:00 PM Eastern
Extended Trading
$670.75 +3.88 (+0.58%)
As of 03/14/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • Regeneron Pharmaceuticals, Inc. reported a strong quarterly earnings result with an earnings per share (EPS) of $12.07, exceeding analysts' expectations of $11.21, indicating robust financial performance.
  • The company has a solid market capitalization of approximately $78.42 billion, reflecting its significant presence and stability in the biopharmaceutical sector.
  • With a current ratio of 4.73, Regeneron Pharmaceuticals, Inc. demonstrates strong liquidity, meaning it has ample short-term assets to cover its liabilities, which is a positive sign for investors.

Cons of Regeneron Pharmaceuticals

  • The stock has experienced a decline, trading down $26.67 recently, which may indicate volatility and potential risks for investors.
  • Analysts have mixed ratings on the stock, with one sell rating and several hold ratings, suggesting uncertainty about its future performance.
  • The PEG ratio of 2.34 indicates that the stock may be overvalued relative to its earnings growth, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$72.91 billion
P/E Ratio
17.42
Consensus Rating
Moderate Buy
Consensus Price Target
$973.13 (+45.9% Upside)
Volume
1.31 million shares
Average Volume
626,581 shares
Today's Range
$657.00
$686.98
50-Day Range
$663.86
$744.83
52-Week Range
$642.00
$1,211.20
Dividend Yield
0.12%
Zoetis stock logo

29. Zoetis NYSE:ZTS

$161.33 +1.27 (+0.80%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$159.90 -1.44 (-0.89%)
As of 03/14/2025 07:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • Zoetis Inc. has shown strong financial performance, with a recent earnings report indicating an EPS of $1.40, surpassing the consensus estimate of $1.37. This suggests robust profitability and effective management.
  • The stock is currently trading at $166.18, which is near its 52-week high of $200.33, indicating strong market confidence and potential for growth.
  • Institutional ownership is high at 92.80%, reflecting strong confidence from large investors, which can be a positive indicator for retail investors.

Cons of Zoetis

  • PNC Financial Services Group Inc. recently reduced its position in Zoetis Inc. by 5.8%, which may signal concerns about the stock's future performance among institutional investors.
  • The stock has experienced volatility, with a recent drop of $5.62 during trading hours, indicating potential instability that could deter risk-averse investors.
  • Despite strong earnings, the price-to-earnings ratio of 30.05 suggests that the stock may be overvalued compared to its earnings, which could lead to a correction.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$71.67 billion
P/E Ratio
29.49
Consensus Rating
Buy
Consensus Price Target
$215.90 (+33.8% Upside)
Volume
2.78 million shares
Average Volume
2.54 million shares
Today's Range
$158.30
$161.43
50-Day Range
$156.43
$175.65
52-Week Range
$144.80
$200.33
Dividend Yield
1.24%
Becton, Dickinson and Company stock logo

30. Becton, Dickinson and Company NYSE:BDX

$226.43 +3.64 (+1.63%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$226.00 -0.43 (-0.19%)
As of 03/14/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • Becton, Dickinson and Company reported earnings per share of $3.43, exceeding analysts' expectations of $3.00 by $0.43, indicating strong financial performance and effective management.
  • The company has a consensus rating of "Buy" from eight investment analysts, suggesting positive sentiment and confidence in its future performance.
  • Barclays and Piper Sandler have recently raised their price targets for Becton, Dickinson and Company to $279.00 and $280.00 respectively, reflecting optimism about the company's growth potential.

Cons of Becton, Dickinson and Company

  • The company's net margin is 8.47%, which may indicate lower profitability compared to competitors, potentially affecting long-term growth prospects.
  • Insider transactions show that executives have sold a total of 5,423 shares worth $1,239,780 in the last 90 days, which could signal a lack of confidence in the company's short-term performance.
  • The payout ratio is 69.10%, suggesting that a significant portion of earnings is being distributed as dividends, which may limit funds available for reinvestment in growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$65.02 billion
P/E Ratio
37.61
Consensus Rating
Buy
Consensus Price Target
$278.29 (+22.9% Upside)
Volume
1.16 million shares
Average Volume
1.52 million shares
Today's Range
$221.98
$226.47
50-Day Range
$222.65
$249.75
52-Week Range
$218.75
$251.99
Dividend Yield
1.81%
Remove Ads
Cencora stock logo

31. Cencora NYSE:COR

$258.08 +2.08 (+0.81%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$258.08 -0.01 (0.00%)
As of 03/14/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is $255.22, reflecting a recent increase of 0.7%, indicating positive market sentiment and potential for further growth.
  • Cencora, Inc. has a solid dividend payout, recently issuing a quarterly dividend of $0.55 per share, which translates to an annualized yield of 0.87%. This can provide a steady income stream for investors.
  • Insider trading activity shows confidence in the company, with the CEO recently selling shares but still holding a significant amount, indicating a belief in the company's future performance.

Cons of Cencora

  • Recent insider sales, including a significant transaction by the EVP, may raise concerns about the executives' confidence in the company's short-term performance.
  • The company's payout ratio is 31.29%, which, while sustainable, indicates that a significant portion of earnings is being distributed as dividends, potentially limiting funds available for reinvestment in growth opportunities.
  • Cencora, Inc. has experienced a decrease in insider ownership, with the CEO's recent sale representing an 8.87% reduction in their stake, which could signal a lack of confidence in the company's future.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$50.05 billion
P/E Ratio
36.71
Consensus Rating
Moderate Buy
Consensus Price Target
$280.20 (+8.6% Upside)
Volume
925,102 shares
Average Volume
1.36 million shares
Today's Range
$252.49
$258.46
50-Day Range
$228.69
$261.65
52-Week Range
$214.77
$263.70
Dividend Yield
0.87%
Takeda Pharmaceutical stock logo

32. Takeda Pharmaceutical NYSE:TAK

$15.02 -0.02 (-0.10%)
Closing price 03/14/2025 03:58 PM Eastern
Extended Trading
$14.90 -0.11 (-0.73%)
As of 03/14/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • Takeda Pharmaceutical Company Limited recently reached a new 52-week high of $15.08, indicating strong market performance and investor confidence.
  • The company reported a quarterly earnings per share (EPS) of $0.42, surpassing analysts' expectations of $0.34, which reflects effective management and operational efficiency.
  • With a market capitalization of approximately $48.29 billion, Takeda Pharmaceutical Company Limited is positioned as a significant player in the pharmaceutical industry, suggesting stability and growth potential.

Cons of Takeda Pharmaceutical

  • The stock has a relatively high price-to-earnings (P/E) ratio of 37.94, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • Despite recent gains, the stock's beta of 0.46 suggests lower volatility compared to the market, which may limit potential high returns for aggressive investors.
  • Takeda Pharmaceutical Company Limited has a net margin of only 4.53%, which may indicate challenges in maintaining profitability compared to competitors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$47.82 billion
P/E Ratio
37.54
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
1.84 million shares
Average Volume
1.80 million shares
Today's Range
$14.89
$15.12
50-Day Range
$12.91
$15.18
52-Week Range
$12.58
$15.22
Dividend Yield
3.58%
Haleon stock logo

33. Haleon NYSE:HLN

$10.15 -0.04 (-0.34%)
Closing price 03/14/2025 03:58 PM Eastern
Extended Trading
$10.18 +0.03 (+0.25%)
As of 03/14/2025 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • Haleon plc reported earnings of $0.05 per share for the latest quarter, indicating a positive performance that may attract investors looking for profitable companies.
  • The company achieved revenue of $3.54 billion, surpassing analyst estimates of $3.38 billion, showcasing strong market demand for its consumer healthcare products.
  • With a return on equity of 14.76%, Haleon plc demonstrates effective management in generating profits from shareholders' equity, which is a positive indicator for potential investors.

Cons of Haleon

  • The stock has a price-to-earnings ratio of 31.15, which may indicate that it is overvalued compared to its earnings, potentially leading to a correction in stock price.
  • Haleon plc's beta is 0.28, suggesting lower volatility compared to the market, which may not appeal to investors looking for high-risk, high-reward opportunities.
  • Despite recent revenue growth, the company faces competition in the consumer healthcare sector, which could impact future profitability and market share.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.97 billion
P/E Ratio
29.87
Consensus Rating
Hold
Consensus Price Target
$10.95 (+7.8% Upside)
Volume
8.13 million shares
Average Volume
6.63 million shares
Today's Range
$10.12
$10.19
50-Day Range
$9.02
$10.68
52-Week Range
$7.89
$10.80
Dividend Yield
1.01%
Alcon stock logo

34. Alcon NYSE:ALC

$89.00 +2.19 (+2.53%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$88.96 -0.04 (-0.05%)
As of 03/14/2025 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • Alcon Inc. has shown a strong fifty-two week performance of 26.72%, indicating a positive trend in its stock price over the past year, which can attract investors looking for growth.
  • The current stock price is $91.98, which reflects the company's market valuation and can be appealing for investors looking to enter at a favorable price point.
  • Institutional ownership stands at 72.64%, suggesting that a significant portion of the company is held by institutional investors, which can indicate confidence in the company's future prospects.

Cons of Alcon

  • There has been a month-to-month decrease in shares shorted, from 3,430,000 to 3,160,000, which may indicate a lack of confidence in the stock's ability to maintain its current price level.
  • The company has experienced a slight decline in its month-to-month change percentage of shares shorted, which could suggest that investors are becoming more cautious about the stock's future performance.
  • Despite a strong fifty-two week performance, the recent performance of 20.37% may indicate a slowdown in growth, which could concern investors looking for consistent upward momentum.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.90 billion
P/E Ratio
38.04
Consensus Rating
Moderate Buy
Consensus Price Target
$103.00 (+15.7% Upside)
Volume
870,081 shares
Average Volume
933,851 shares
Today's Range
$87.33
$89.08
50-Day Range
$82.70
$94.76
52-Week Range
$77.54
$101.10
Dividend Yield
0.28%
Edwards Lifesciences stock logo

35. Edwards Lifesciences NYSE:EW

$69.37 +1.42 (+2.09%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$69.15 -0.22 (-0.31%)
As of 03/14/2025 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The company reported a strong quarterly earnings result with an EPS of $0.59, exceeding analysts' expectations of $0.55, indicating robust financial performance.
  • Edwards Lifesciences Co. has a high net margin of 72.93%, suggesting that it retains a significant portion of revenue as profit, which is attractive for investors looking for profitability.
  • Institutional investors own 79.46% of the company's stock, indicating strong confidence from large financial entities, which can be a positive signal for individual investors.

Cons of Edwards Lifesciences

  • Insider selling has occurred, with a total of 37,739 shares sold recently, which may raise concerns about the confidence of company executives in the stock's future performance.
  • The stock has experienced a slight decline of 0.3% recently, which could indicate short-term volatility and uncertainty in the market.
  • Despite a strong net margin, the P/E ratio of 10.24 may suggest that the stock is overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.78 billion
P/E Ratio
9.95
Consensus Rating
Hold
Consensus Price Target
$79.95 (+15.3% Upside)
Volume
3.59 million shares
Average Volume
4.52 million shares
Today's Range
$67.78
$69.66
50-Day Range
$67.92
$76.23
52-Week Range
$58.93
$96.12
Dividend Yield
N/A
Remove Ads
Veeva Systems stock logo

36. Veeva Systems NYSE:VEEV

$233.84 +6.04 (+2.65%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$227.72 -6.11 (-2.61%)
As of 03/14/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • Recent upgrades from multiple financial institutions, including Scotiabank and Royal Bank of Canada, indicate strong confidence in Veeva Systems Inc.'s performance, with price targets set at $245.00 and $285.00 respectively.
  • The stock has a consensus rating of "Moderate Buy" from analysts, suggesting that the majority believe the stock will perform well in the near future.
  • Veeva Systems Inc. has a robust position in the life sciences industry, providing cloud-based software solutions that are increasingly in demand, especially in a post-pandemic world.

Cons of Veeva Systems

  • Some analysts, including those from The Goldman Sachs Group, have downgraded their ratings, indicating potential concerns about the stock's future performance.
  • There are two analysts who have issued sell ratings, which may suggest that there are significant risks or uncertainties surrounding the company's future growth.
  • KeyCorp recently decreased their target price from $285.00 to $255.00, which could indicate a more cautious outlook on the stock's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$37.96 billion
P/E Ratio
57.74
Consensus Rating
Moderate Buy
Consensus Price Target
$255.28 (+9.2% Upside)
Volume
903,575 shares
Average Volume
1.21 million shares
Today's Range
$229.41
$234.13
50-Day Range
$210.81
$247.10
52-Week Range
$170.25
$258.93
Dividend Yield
N/A
GE HealthCare Technologies stock logo

37. GE HealthCare Technologies NASDAQ:GEHC

$81.97 +0.52 (+0.64%)
Closing price 03/14/2025 04:00 PM Eastern
Extended Trading
$82.25 +0.28 (+0.34%)
As of 03/14/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The stock has recently been upgraded by multiple analysts, with target prices raised significantly, indicating strong market confidence. For instance, Wells Fargo increased their target price from $96.00 to $103.00.
  • GE HealthCare Technologies Inc. reported earnings per share (EPS) of $1.45, surpassing analysts' expectations of $1.26, which reflects strong financial performance and operational efficiency.
  • The current stock price is $85.59, which is below the consensus target price of $98.75, suggesting potential for price appreciation.

Cons of GE HealthCare Technologies

  • The company has a debt-to-equity ratio of 0.88, which, while manageable, indicates that it relies on debt financing, potentially increasing financial risk in a rising interest rate environment.
  • Despite a strong EPS report, the revenue of $5.32 billion was slightly below analyst estimates of $5.33 billion, which may raise concerns about future growth prospects.
  • The stock has a price-to-earnings (P/E) ratio of 19.77, which may be considered high compared to industry averages, suggesting that the stock could be overvalued.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$37.48 billion
P/E Ratio
18.93
Consensus Rating
Moderate Buy
Consensus Price Target
$98.75 (+20.5% Upside)
Volume
5.21 million shares
Average Volume
3.08 million shares
Today's Range
$80.40
$82.33
50-Day Range
$81.45
$93.48
52-Week Range
$74.51
$94.80
Dividend Yield
0.16%
argenx stock logo

38. argenx NASDAQ:ARGX

$604.96 +23.75 (+4.09%)
Closing price 03/14/2025 04:00 PM Eastern
Extended Trading
$591.24 -13.73 (-2.27%)
As of 03/14/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenx

Pros of argenx

  • argenx SE's lead product candidate, efgartigimod, is showing promise in treating multiple autoimmune diseases, which could lead to significant revenue growth as these therapies gain approval and market traction.
  • The company has a strong institutional backing, with 60.32% of its stock owned by institutional investors and hedge funds, indicating confidence in its long-term prospects.
  • As of the latest trading session, argenx SE's stock price is $626.13, reflecting a robust market capitalization of $38.04 billion, which suggests a solid position in the biotechnology sector.

Cons of argenx

  • The stock has a high P/E ratio of -711.51, which indicates that the company is not currently profitable, raising concerns about its financial sustainability.
  • Recent trading activity shows volatility, with shares trading down 2.8% in a single session, which may indicate market uncertainty regarding the company's future performance.
  • Despite positive analyst ratings, one research analyst has issued a sell rating, suggesting that there are differing opinions on the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.76 billion
P/E Ratio
-687.45
Consensus Rating
Moderate Buy
Consensus Price Target
$687.00 (+13.6% Upside)
Volume
575,781 shares
Average Volume
285,765 shares
Today's Range
$582.41
$605.43
50-Day Range
$571.00
$671.74
52-Week Range
$349.86
$678.21
Dividend Yield
N/A
IDEXX Laboratories stock logo

39. IDEXX Laboratories NASDAQ:IDXX

$415.30 +9.01 (+2.22%)
Closing price 03/14/2025 04:00 PM Eastern
Extended Trading
$411.04 -4.26 (-1.02%)
As of 03/14/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The stock has received multiple upgrades from analysts, with a recent target price increase from Bank of America to $535.00, indicating strong market confidence in the company's growth potential.
  • IDEXX Laboratories, Inc. has a diverse product portfolio that serves various markets, including companion animal veterinary, livestock, and water testing, which can help mitigate risks associated with market fluctuations.
  • Recent insider trading activity shows confidence from executives, with significant stock sales by insiders like George Fennell and M Anne Szostak, suggesting they believe in the company's future performance despite their reduced holdings.

Cons of IDEXX Laboratories

  • Insider sales have resulted in a significant decrease in ownership percentages, with George Fennell and M Anne Szostak reducing their stakes by 54.98% and 49.50%, respectively, which may raise concerns about their confidence in the company's future.
  • Despite positive analyst ratings, the stock has seen fluctuations in target prices, indicating potential volatility that could affect short-term investors.
  • The company operates in competitive markets, and any changes in regulations or market dynamics could impact its profitability and growth trajectory.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.78 billion
P/E Ratio
38.92
Consensus Rating
Moderate Buy
Consensus Price Target
$533.75 (+28.5% Upside)
Volume
645,193 shares
Average Volume
550,418 shares
Today's Range
$409.00
$418.86
50-Day Range
$406.29
$469.04
52-Week Range
$398.50
$548.88
Dividend Yield
N/A
Agilent Technologies stock logo

40. Agilent Technologies NYSE:A

$121.53 +4.20 (+3.58%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$121.13 -0.40 (-0.33%)
As of 03/14/2025 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • Agilent Technologies, Inc. recently reported earnings per share of $1.31, exceeding analysts' expectations, which indicates strong financial performance and potential for future growth.
  • The company has a solid market capitalization of approximately $35.89 billion, reflecting its stability and position in the market.
  • Agilent Technologies, Inc. has a current ratio of 2.20, suggesting that it has more than enough assets to cover its short-term liabilities, which is a positive indicator of financial health.

Cons of Agilent Technologies

  • The stock has experienced volatility, with a 12-month high of $155.35, indicating potential fluctuations that could pose risks for investors.
  • Agilent Technologies, Inc. has a P/E ratio of 28.96, which may suggest that the stock is overvalued compared to its earnings, potentially deterring value-focused investors.
  • The company has a beta of 1.11, indicating that its stock price is slightly more volatile than the market, which could lead to higher risk for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.45 billion
P/E Ratio
27.94
Consensus Rating
Moderate Buy
Consensus Price Target
$146.15 (+20.3% Upside)
Volume
2.98 million shares
Average Volume
2.01 million shares
Today's Range
$117.50
$122.05
50-Day Range
$117.21
$152.87
52-Week Range
$117.17
$155.35
Dividend Yield
0.85%
Remove Ads
ResMed stock logo

41. ResMed NYSE:RMD

$224.48 +4.76 (+2.17%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$220.16 -4.33 (-1.93%)
As of 03/14/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • ResMed Inc. has a strong earnings forecast, with analysts expecting an EPS of 9.47 for the current fiscal year, indicating potential for growth and profitability.
  • The company recently reported a quarterly earnings per share of $2.43, surpassing analysts' expectations, which reflects its strong operational performance.
  • ResMed Inc. has declared a quarterly dividend of $0.53 per share, translating to an annualized dividend of $2.12 and a yield of 0.91%, providing a return on investment for shareholders.

Cons of ResMed

  • Recent analyst downgrades, including a shift from a "buy" to a "hold" rating, may indicate concerns about the stock's future performance and market sentiment.
  • The company has a relatively low dividend payout ratio of 25.03%, which may suggest limited returns for income-focused investors compared to other options in the market.
  • Insider selling activity, with significant shares sold recently, could raise red flags about the company's future prospects and insider confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.97 billion
P/E Ratio
26.50
Consensus Rating
Moderate Buy
Consensus Price Target
$243.82 (+8.6% Upside)
Volume
746,942 shares
Average Volume
967,259 shares
Today's Range
$219.19
$224.64
50-Day Range
$219.31
$257.63
52-Week Range
$172.19
$263.05
Dividend Yield
0.91%
IQVIA stock logo

42. IQVIA NYSE:IQV

$185.40 +3.97 (+2.19%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$193.00 +7.60 (+4.10%)
As of 03/14/2025 06:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • IQVIA Holdings Inc. has a strong return on equity of 28.81%, indicating effective management and profitability relative to shareholder equity, which can attract investors looking for efficient companies.
  • The company reported a net margin of 8.91%, suggesting that it retains a good portion of revenue as profit, which is a positive sign for potential investors.
  • Recent analyst ratings show a consensus target price of $249.05, indicating potential upside from the current stock price, which is beneficial for investors seeking growth.

Cons of IQVIA

  • The company recently missed earnings per share (EPS) estimates by $0.21, reporting $2.90 instead of the expected $3.11, which may raise concerns about its short-term financial performance.
  • IQVIA Holdings Inc. has a relatively high debt-to-equity ratio of 2.12, indicating that it relies heavily on debt financing, which can be risky if market conditions change.
  • Some analysts have downgraded their price targets for the stock, reflecting a cautious outlook that could deter potential investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.69 billion
P/E Ratio
24.72
Consensus Rating
Moderate Buy
Consensus Price Target
$249.05 (+34.3% Upside)
Volume
1.10 million shares
Average Volume
1.23 million shares
Today's Range
$182.03
$185.53
50-Day Range
$181.53
$209.76
52-Week Range
$179.28
$256.34
Dividend Yield
N/A
Alnylam Pharmaceuticals stock logo

43. Alnylam Pharmaceuticals NASDAQ:ALNY

$241.76 +0.01 (+0.00%)
Closing price 03/14/2025 04:00 PM Eastern
Extended Trading
$243.88 +2.12 (+0.87%)
As of 03/14/2025 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • Recent analyst upgrades have significantly increased the price targets for Alnylam Pharmaceuticals, Inc., with HC Wainwright raising their target from $400.00 to $500.00, indicating strong growth potential.
  • The stock is currently trading at $242.43, which may present a buying opportunity for investors looking to enter at a lower price before potential upward movements.
  • Alnylam Pharmaceuticals, Inc. has a consensus rating of "Moderate Buy" from analysts, suggesting overall positive sentiment and confidence in the company's future performance.

Cons of Alnylam Pharmaceuticals

  • The company reported earnings per share of ($0.65), missing analysts' expectations, which may raise concerns about its profitability and operational efficiency.
  • Alnylam Pharmaceuticals, Inc. has a high debt-to-equity ratio of 15.27, indicating that the company relies heavily on debt financing, which can be risky if not managed properly.
  • Insider selling has been notable, with executives selling a total of 72,986 shares valued at over $20 million in the last 90 days, which could signal a lack of confidence in the company's near-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.30 billion
P/E Ratio
-111.41
Consensus Rating
Moderate Buy
Consensus Price Target
$304.26 (+25.9% Upside)
Volume
478,821 shares
Average Volume
788,755 shares
Today's Range
$239.53
$244.04
50-Day Range
$233.07
$278.99
52-Week Range
$141.98
$304.39
Dividend Yield
N/A
Cardinal Health stock logo

44. Cardinal Health NYSE:CAH

$128.20 +1.93 (+1.52%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$128.46 +0.26 (+0.20%)
As of 03/14/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The stock is currently trading at approximately $125.82, which is near its 50-day moving average, indicating stability in its recent performance.
  • Cardinal Health, Inc. reported earnings per share (EPS) of $1.93 for the last quarter, exceeding analysts' expectations of $1.74, showcasing strong financial performance.
  • The company has a market capitalization of $30.65 billion, reflecting its significant size and stability in the healthcare sector.

Cons of Cardinal Health

  • The company has a negative return on equity of 59.57%, indicating that it is not effectively generating profit from its equity, which could raise concerns about management efficiency.
  • Cardinal Health, Inc. has a net margin of only 0.59%, suggesting that it retains a small portion of revenue as profit, which may limit growth potential.
  • The stock's beta of 0.66 indicates lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.97 billion
P/E Ratio
23.92
Consensus Rating
Moderate Buy
Consensus Price Target
$139.36 (+8.7% Upside)
Volume
1.86 million shares
Average Volume
2.45 million shares
Today's Range
$125.14
$128.37
50-Day Range
$119.48
$130.65
52-Week Range
$93.17
$132.84
Dividend Yield
1.60%
Humana stock logo

45. Humana NYSE:HUM

$253.11 +1.38 (+0.55%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$252.28 -0.84 (-0.33%)
As of 03/14/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • Humana Inc. has shown strong institutional support, with 92.38% of its stock owned by hedge funds and other institutional investors, indicating confidence in the company's future performance.
  • The recent stock price of Humana Inc. is $256.69, reflecting a stable market position and potential for growth, especially considering its market capitalization of approximately $30.91 billion.
  • Humana Inc. has experienced significant increases in holdings from major investors, such as FMR LLC, which raised its stake by 23.4%, suggesting positive sentiment and potential for future appreciation.

Cons of Humana

  • Despite the strong institutional backing, the recent insider selling by Timothy S. Huval, who sold 3,703 shares, may raise concerns about insider confidence in the company's short-term performance.
  • The stock has shown volatility, with a recent trading drop of $10.11, which could indicate market uncertainty and potential risks for investors.
  • Humana Inc. has a price-to-earnings (P/E) ratio of 22.74, which, while not excessively high, may suggest that the stock is overvalued compared to its earnings, potentially limiting upside for new investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.55 billion
P/E Ratio
25.44
Consensus Rating
Hold
Consensus Price Target
$285.68 (+12.9% Upside)
Volume
1.33 million shares
Average Volume
1.72 million shares
Today's Range
$251.24
$259.25
50-Day Range
$249.32
$303.57
52-Week Range
$213.31
$406.46
Dividend Yield
1.41%
Remove Ads
Centene stock logo

46. Centene NYSE:CNC

$58.27 +0.31 (+0.53%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$58.19 -0.08 (-0.13%)
As of 03/14/2025 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. More about Centene

Pros of Centene

  • Recent insider buying activity, including a significant purchase by Director Thomas Greco, indicates confidence in the company's future performance. Greco acquired 17,000 shares at an average price of $59.75, suggesting he believes the stock is undervalued.
  • Centene Co. has received multiple analyst upgrades, with Barclays raising its price target to $93.00 and UBS Group upgrading the stock to a "buy" rating. These endorsements from analysts can positively influence investor sentiment and stock performance.
  • The current stock price is $58.27, which is near its 52-week low of $55.03. This may present a buying opportunity for investors looking for value, especially considering the stock's previous high of $80.59.

Cons of Centene

  • Bank Julius Baer & Co. Ltd Zurich significantly reduced its stake in Centene by 98.2%, selling 738,899 shares. Such a drastic reduction by a major institutional investor may signal a lack of confidence in the company's future prospects.
  • Despite recent upgrades, one analyst has issued a sell rating on the stock, indicating that there are differing opinions on the stock's future performance, which can create uncertainty for potential investors.
  • Centene's stock has recently traded down, reflecting a 2.0% decrease in value. This downward trend can be concerning for investors, as it may indicate broader market challenges or company-specific issues.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$28.90 billion
P/E Ratio
9.34
Consensus Rating
Moderate Buy
Consensus Price Target
$79.92 (+37.2% Upside)
Volume
4.32 million shares
Average Volume
4.47 million shares
Today's Range
$57.47
$58.56
50-Day Range
$55.94
$65.88
52-Week Range
$55.03
$80.59
Dividend Yield
N/A
DexCom stock logo

47. DexCom NASDAQ:DXCM

$70.69 +2.21 (+3.23%)
Closing price 03/14/2025 04:00 PM Eastern
Extended Trading
$70.43 -0.26 (-0.36%)
As of 03/14/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • Recent upgrades from analysts, including a price target increase to $104.00, indicate strong market confidence in DexCom, Inc.'s growth potential.
  • The company reported a return on equity of 30.14%, showcasing its ability to generate profit from shareholders' equity, which is a positive indicator for investors.
  • DexCom, Inc. has a consensus rating of "Moderate Buy" from analysts, with 13 buy ratings and only 4 hold ratings, suggesting strong market support.

Cons of DexCom

  • The company missed analysts' consensus estimates for earnings per share (EPS) by $0.05, which may raise concerns about its short-term profitability.
  • Recent insider selling, including significant sales by the CEO and other executives, could signal a lack of confidence in the company's near-term performance.
  • Despite a strong market position, the stock has experienced volatility, with a one-year low of $62.34, which may deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$27.62 billion
P/E Ratio
49.43
Consensus Rating
Moderate Buy
Consensus Price Target
$99.82 (+41.2% Upside)
Volume
4.90 million shares
Average Volume
3.91 million shares
Today's Range
$68.59
$70.77
50-Day Range
$68.48
$90.75
52-Week Range
$62.34
$142.00
Dividend Yield
N/A
Mettler-Toledo International stock logo

48. Mettler-Toledo International NYSE:MTD

$1,231.32 +29.33 (+2.44%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$1,223.08 -8.23 (-0.67%)
As of 03/14/2025 05:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. More about Mettler-Toledo International

Pros of Mettler-Toledo International

  • The company recently reported earnings per share of $12.41, exceeding analysts' expectations of $11.76, indicating strong financial performance.
  • Mettler-Toledo International Inc. has a market capitalization of approximately $27.04 billion, reflecting its significant size and stability in the market.
  • Current stock price is around $1,292.69, which is near its 52-week high of $1,546.93, suggesting strong investor interest and potential for growth.

Cons of Mettler-Toledo International

  • The company has a negative return on equity of 591.54%, which may raise concerns about its profitability and efficiency in generating returns for shareholders.
  • Insider selling activity, including a significant sale by Gerry Keller, could indicate a lack of confidence in the company's short-term performance.
  • The stock has experienced volatility, with a beta of 1.15, suggesting it may be more sensitive to market fluctuations compared to the overall market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$25.75 billion
P/E Ratio
30.38
Consensus Rating
Hold
Consensus Price Target
$1,380.50 (+12.1% Upside)
Volume
90,613 shares
Average Volume
128,406 shares
Today's Range
$1,206.59
$1,232.45
50-Day Range
$1,201.93
$1,390.00
52-Week Range
$1,142.91
$1,546.93
Dividend Yield
N/A
Beigene stock logo

49. Beigene NASDAQ:ONC

$259.19 +4.62 (+1.81%)
As of 03/14/2025 04:00 PM Eastern

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Market Capitalization
$25.36 billion
P/E Ratio
-31.46
Consensus Rating
Buy
Consensus Price Target
$327.00 (+26.2% Upside)
Volume
315,031 shares
Average Volume
457,164 shares
Today's Range
$252.01
$260.00
50-Day Range
$0.00
$0.00
52-Week Range
$126.97
$287.88
Dividend Yield
N/A
Koninklijke Philips stock logo

50. Koninklijke Philips NYSE:PHG

$26.76 +0.65 (+2.47%)
Closing price 03/14/2025 03:59 PM Eastern
Extended Trading
$26.76 0.00 (0.00%)
As of 03/14/2025 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. More about Koninklijke Philips

Pros of Koninklijke Philips

  • Analysts have assigned a consensus rating of "Moderate Buy," indicating positive sentiment and potential for stock appreciation.
  • Recent institutional investments, such as C2P Capital Advisory Group acquiring shares valued at approximately $263,000, suggest growing confidence in the company's future.
  • The current stock price is $27.03, which is relatively close to its 52-week low of $19.10, potentially offering a buying opportunity for investors looking for value.

Cons of Koninklijke Philips

  • The stock has a negative price-to-earnings (P/E) ratio of -32.22, which may indicate challenges in profitability and could deter risk-averse investors.
  • Recent downgrades from analysts, including a shift from "buy" to "hold," suggest that some experts are cautious about the company's short-term performance.
  • With a 52-week high of $32.91, the stock has seen significant volatility, which may pose risks for investors seeking stable returns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$25.15 billion
P/E Ratio
-31.85
Consensus Rating
Moderate Buy
Consensus Price Target
N/A
Volume
922,500 shares
Average Volume
874,909 shares
Today's Range
$26.49
$26.76
50-Day Range
$24.92
$28.60
52-Week Range
$19.10
$32.91
Dividend Yield
3.32%
Remove Ads